Number of participants tranquillised at endpoint of the study (Desired sedation/tranquillisation) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Paliperidone palmitate leads to lower leaving the study early ‐ any reason Reported by trial author compared with placebo (high certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate probably leads to lower no clinically important change Number of people whose PANSS score… compared with placebo (moderate certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate probably leads to lower relapse: recurrence of psychotic symptoms Reported by trial author… compared with placebo (moderate certainty).
1 finding from 1 review
Average change in prolactin in men Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review
Average change in prolactin in women Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review
Change in weight (kg) · patients with schizophrenia
1 finding from 1 review
Health‐related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 2. Relapse ‐ short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1. Death ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Death ‐ medium term · patients with schizophrenia
1 finding from 1 review
Adverse effect: 2. General ‐ Short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effect: 2. General ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 3. Specific ‐ cardiovascular ‐ short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effects: 3. Specific ‐ cardiovascular ‐ short term compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Poor compliance with study protocol · people with schizophrenia or like psychosis
The intervention may leads to lower poor compliance with study protocol (low certainty).
1 finding from 1 review
Intervention not reported
Relapse · people with schizophrenia or like psychosis
The intervention may leads to lower relapse (low certainty).
1 finding from 1 review
Intervention not reported
Weight gain (equal or greater then 7% of baseline) · people with schizophrenia or like psychosis
The intervention may leads to higher weight gain (equal or greater then 7% of baseline) (low certainty).
1 finding from 1 review
Intervention not reported
Concomitant medication (Anxiolytic ‐ Lorazepam) · people with schizophrenia or like psychosis
The intervention may leads to lower concomitant medication (Anxiolytic ‐ Lorazepam) (low certainty).
1 finding from 1 review